Literature DB >> 12533741

Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study.

Görgün Akpek1, Wichai Chinratanalab, Linda A Lee, Michael Torbenson, Jason P Hallick, Viki Anders, Georgia B Vogelsang.   

Abstract

The original histopathologic description of chronic graft-versus-host disease (CGVHD) of the gastrointestinal (GI) tract was from autopsy series. There is little information on the evaluation of living patients with CGVHD and GI symptoms. We reviewed data on 40 consecutive patients with CGVHD and persistent GI symptoms who underwent endoscopic examinations. The diagnosis of CGVHD in these 40 patients was made on the basis of clinical criteria and confirmed by histology of other involved organs in 70%. Patients had progressive (in 19 patients, or 48%), quiescent (in 11, or 27%) or de novo-type (in 10, or 25%) onset of their CGVHD. Four groups were defined based on the following histologic criteria: (1) consistent with acute GI GVHD if there was marked apoptosis with or without cryptitis, (2) suggestive of acute GI GVHD if there was scattered apoptosis with or without cryptitis, (3) suggestive of chronic GI GVHD if there were at least 2 histologic indicators of chronicity such as fibrosis and significant crypt distortion, and (4) no histologic evidence of GVHD. Results of microbiologic, radiologic, and malabsorption studies, if performed, were also retrieved. Median time from diagnosis of CGVHD to GI endoscopy was 4.5 months (0-109 months). The major GI symptoms at the time of endoscopy were diarrhea, abdominal pain/cramping, nausea/vomiting, weight loss, dysphagia, and early satiety. The endoscopic examination was nonspecific for the diagnosis of GI GVHD except for diffuse mucosal sloughing. Based on the histologic criteria in 22 patients with biopsies, 13 cases (59%) were considered to have acute GI GVHD, and 3 cases (14%) were felt to show possible chronic GI GVHD; changes of both acute and chronic GVHD were seen in 6 (27%) cases. GI dysmotility was diagnosed in 7 (18%) patients, including 2 of the patients who had histologic changes suggestive of chronic GVHD. Other causes of the GI symptoms included infection, drug side effect, and malabsorption. In conclusion, GI involvement by acute GVHD appears to be a major cause of persistent GI symptoms in patients with chronic GVHD. An isolated form of chronic GI GVHD confirmed by histology is an uncommon phenomenon in the actual clinical setting. Copyright 2003 American Society for Blood and Marrow Transplantation

Entities:  

Mesh:

Year:  2003        PMID: 12533741     DOI: 10.1053/bbmt.2003.49999

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  19 in total

1.  Cord colitis syndrome: a cause of granulomatous inflammation in the upper and lower gastrointestinal tract.

Authors:  Nitin K Gupta; Ricard Masia
Journal:  Am J Surg Pathol       Date:  2013-07       Impact factor: 6.394

2.  NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report.

Authors:  Howard M Shulman; Diana M Cardona; Joel K Greenson; Sangeeta Hingorani; Thomas Horn; Elisabeth Huber; Andreas Kreft; Thomas Longerich; Thomas Morton; David Myerson; Victor G Prieto; Avi Rosenberg; Nathaniel Treister; Kay Washington; Mirjana Ziemer; Steven Z Pavletic; Stephanie J Lee; Mary E D Flowers; Kirk R Schultz; Madan Jagasia; Paul J Martin; Georgia B Vogelsang; David E Kleiner
Journal:  Biol Blood Marrow Transplant       Date:  2015-01-29       Impact factor: 5.742

3.  The treatment of chronic graft-versus-host disease: consensus recommendations of experts from Germany, Austria, and Switzerland.

Authors:  Daniel Wolff; Hartmut Bertz; Hildegard Greinix; Anita Lawitschka; Jörg Halter; Ernst Holler
Journal:  Dtsch Arztebl Int       Date:  2011-10-28       Impact factor: 5.594

4.  National Cancer Institute-National Heart, Lung and Blood Institute/pediatric Blood and Marrow Transplant Consortium First International Consensus Conference on late effects after pediatric hematopoietic cell transplantation: long-term organ damage and dysfunction.

Authors:  Michael L Nieder; George B McDonald; Aiko Kida; Sangeeta Hingorani; Saro H Armenian; Kenneth R Cooke; Michael A Pulsipher; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-01       Impact factor: 5.742

5.  Treatment of Gastrointestinal Acute Graft-Versus-Host Disease.

Authors:  William A Ross
Journal:  Curr Treat Options Gastroenterol       Date:  2005-06

6.  Adenosine A₂A receptor agonist-mediated increase in donor-derived regulatory T cells suppresses development of graft-versus-host disease.

Authors:  Kyu Lee Han; Stephenie V M Thomas; Sherry M Koontz; Cattlena M Changpriroa; Seung-Kwon Ha; Harry L Malech; Elizabeth M Kang
Journal:  J Immunol       Date:  2012-12-07       Impact factor: 5.422

7.  Simultaneous occurrence of gastric antral vascular ectasia and protein-losing enteropathy in chronic graft-versus-host disease.

Authors:  Masahiro Hirayama; Eiichi Azuma; Atsuko Nakazawa; Shotaro Iwamoto; Hidemi Toyoda; Yoshihiro Komada
Journal:  Int J Hematol       Date:  2013-02-03       Impact factor: 2.490

8.  Endoscopic diagnosis of gastrointestinal graft-versus-host disease.

Authors:  Chun-Fang Xu; Lan-Xiang Zhu; Xiao-Ming Xu; Wei-Chang Chen; De-Pei Wu
Journal:  World J Gastroenterol       Date:  2008-04-14       Impact factor: 5.742

9.  Prognostic implications of the NIH consensus criteria in children with chronic graft-versus-host disease.

Authors:  Jae Wook Lee; Dae-Hyoung Lee; Pil-Sang Jang; Mi-Sung Yi; Nack-Gyun Chung; Bin Cho; Dae-Chul Jeong; Hack-Ki Kim
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759

10.  Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients.

Authors:  W Kreisel; M Dahlberg; H Bertz; J Harder; K Potthoff; P Deibert; A Schmitt-Graeff; J Finke
Journal:  Bone Marrow Transplant       Date:  2011-06-27       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.